LYKALABS

Lyka Labs Limited

Pharmaceutical formulations manufacturer for domestic and export markets

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

lykalabs.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹87.79
Market cap
318 Cr
Stock P/E
Loss (TTM EPS ₹-2.50)
P/B
3.45
ROE (FY26)
-11.0%
ROCE (FY26)
-6.1%
Operating margin (FY26)
-9.3%
Debt / equity (FY26)
0.53
OCF / EBITDA (3Y)
29.6%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Lyka Labs is a pharmaceutical company that reports a single business segment, "Pharmaceuticals", with its registered office at the G.I.D.C. Industrial Estate in Ankleshwar and a corporate office in Mumbai.

Company snapshot

103rdBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Concerns
  • ✗Net margin is negative — the company is spending more than it earns right now.
3 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales28 Cr33 Cr28 Cr30 Cr41 Cr34 Cr33 Cr33 Cr37 Cr31 Cr28 Cr42 Cr
Operating expenses (approx.)24 Cr26 Cr26 Cr26 Cr36 Cr29 Cr29 Cr29 Cr39 Cr29 Cr34 Cr38 Cr
EBITDA4 Cr7 Cr2 Cr4 Cr5 Cr5 Cr4 Cr4 Cr-3 Cr2 Cr-6 Cr5 Cr
OPM %14.9%21.1%7.3%12.3%12.0%15.4%12.2%11.2%-6.9%5.4%-23.0%10.7%
Other income0.25 Cr0.54 Cr0.29 Cr0.56 Cr0.03 Cr0.83 Cr0.82 Cr0.63 Cr1 Cr1 Cr0.61 Cr0.42 Cr
Interest1 Cr1 Cr1 Cr0.65 Cr0.54 Cr0.61 Cr0.47 Cr0.85 Cr0.79 Cr0.82 Cr0.70 Cr1 Cr
Depreciation4 Cr3 Cr3 Cr2 Cr2 Cr2 Cr1 Cr2 Cr2 Cr2 Cr2 Cr2 Cr
Profit before tax-0.79 Cr3 Cr-2 Cr2 Cr3 Cr4 Cr3 Cr1 Cr-4 Cr-0.16 Cr-9 Cr2 Cr
Tax %22.3%38.7%-27.3%30.8%26.6%24.3%32.8%26.3%26.7%5.6%6.1%-5.1%
Net profit-0.62 Cr2 Cr-2 Cr1 Cr2 Cr3 Cr2 Cr1.00 Cr-3 Cr-0.15 Cr-8 Cr2 Cr
EPS (₹)₹-0.16₹0.53₹-3.83₹0.40₹0.58₹0.75₹0.49₹0.25₹-0.94—₹-2.13₹0.57

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales117 Cr61 Cr71 Cr61 Cr86 Cr194 Cr93 Cr111 Cr138 Cr128 CrSign in free for the trailing twelve months
Operating expenses (approx.)94 Cr66 Cr73 Cr65 Cr67 Cr93 Cr76 Cr95 Cr121 Cr132 CrSign in free for the trailing twelve months
EBITDA23 Cr-5 Cr-2 Cr-4 Cr20 Cr101 Cr17 Cr16 Cr18 Cr-3 CrSign in free for the trailing twelve months
OPM %19.5%-8.5%-2.7%-6.0%22.8%52.1%18.1%14.1%12.9%-2.7%Sign in free for the trailing twelve months
Other income2 Cr2 Cr2 Cr3 Cr2 Cr2 Cr3 Cr1 Cr2 Cr3 CrSign in free for the trailing twelve months
Interest19 Cr8 Cr7 Cr20 Cr26 Cr20 Cr12 Cr5 Cr2 Cr3 CrSign in free for the trailing twelve months
Depreciation10 Cr11 Cr7 Cr8 Cr8 Cr17 Cr14 Cr13 Cr7 Cr8 CrSign in free for the trailing twelve months
Profit before tax-8 Cr-20 Cr-15 Cr-62 Cr-16 Cr60 Cr-13 Cr-0.93 Cr11 Cr-12 CrSign in free for the trailing twelve months
Tax %18.6%5.2%58.8%-1.2%26.0%34.8%0.1%-180.6%28.7%11.4%Sign in free for the trailing twelve months
Net profit-7 Cr-19 Cr-6 Cr-63 Cr-12 Cr39 Cr-13 Cr-3 Cr8 Cr-10 CrSign in free for the trailing twelve months
EPS (₹)₹-2.57₹-6.71₹-1.79₹-27.29₹-4.07₹13.57₹-4.63₹-0.79₹2.22₹-2.81Sign in free for the trailing twelve months
Dividend payout %—————0.0%——0.0%—Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital22 Cr28 Cr28 Cr29 Cr29 Cr29 Cr31 Cr33 Cr36 Cr36 Cr
Reserves16 Cr25 Cr17 Cr-43 Cr-54 Cr-15 Cr15 Cr35 Cr68 Cr57 Cr
Borrowings86 Cr51 Cr96 Cr141 Cr162 Cr130 Cr72 Cr57 Cr38 Cr48 Cr
Other liabilities121 Cr126 Cr76 Cr74 Cr53 Cr43 Cr34 Cr31 Cr35 Cr35 Cr
Total liabilities252 Cr235 Cr217 Cr200 Cr190 Cr186 Cr152 Cr157 Cr176 Cr175 Cr
Fixed assets (net)82 Cr77 Cr74 Cr73 Cr67 Cr69 Cr49 Cr47 Cr77 Cr80 Cr
CWIP17 Cr17 Cr18 Cr17 Cr16 Cr16 Cr15 Cr22 Cr0.20 Cr2 Cr
Investments0.26 Cr0.23 Cr0.02 Cr0.02 Cr0.02 Cr25 Cr0.05 Cr0.09 Cr0.04 Cr0.03 Cr
Loans & advances——0.64 Cr0.08 Cr0.07 Cr0.04 Cr0.08 Cr3 Cr0.05 Cr0.05 Cr
Inventories13 Cr11 Cr7 Cr7 Cr4 Cr8 Cr7 Cr10 Cr12 Cr14 Cr
Trade receivables29 Cr20 Cr15 Cr8 Cr9 Cr18 Cr20 Cr27 Cr43 Cr35 Cr
Cash & bank5 Cr2 Cr2 Cr10 Cr7 Cr17 Cr12 Cr6 Cr1 Cr1 Cr
Other assets105 Cr107 Cr102 Cr86 Cr86 Cr32 Cr49 Cr42 Cr42 Cr42 Cr
Total assets252 Cr235 Cr217 Cr200 Cr190 Cr186 Cr152 Cr157 Cr176 Cr175 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity31 Cr11 Cr27 Cr5 Cr9 Cr79 Cr9 Cr2 Cr2 Cr5 Cr
Cash from investing-13 Cr-3 Cr-4 Cr-0.11 Cr-0.16 Cr9 Cr7 Cr-9 Cr-12 Cr-9 Cr
Cash from financing-19 Cr-10 Cr-23 Cr3 Cr-12 Cr-64 Cr-22 Cr2 Cr5 Cr4 Cr
Net cash flow-0.43 Cr-3 Cr-0.86 Cr8 Cr-3 Cr24 Cr-5 Cr-12 Cr-5 Cr0.02 Cr
Free cash flow (OCF − Capex)18 Cr7 Cr22 Cr4 Cr8 Cr79 Cr0.77 Cr-7 Cr-14 Cr-6 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %8.1%-11.1%-5.8%-9.3%8.3%55.9%-1.1%3.1%9.5%-6.1%
ROE %-12.4%-29.6%-13.9%——289.1%-28.9%-3.8%7.7%-11.0%
Debtor days9112375483735798911399
Inventory days136221169183127111110109122156
Days payable403487557461435325148137147192
Cash conversion cycle-176-143-313-231-271-18040608963
OCF / EBITDA %137.8%———44.8%78.3%53.2%11.3%10.6%—
OCF / EBITDA % (3 years)——438.2%—288.0%79.7%70.5%67.3%25.0%29.6%
Debt / equity2.280.962.13——9.721.580.840.370.53
Current ratio0.380.300.400.540.590.531.361.351.451.17
Net debt / EBITDA3.55———7.851.113.563.272.04—